BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16823893)

  • 1. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
    Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
    Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
    Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
    Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
    J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH.
    Natrajan R; Williams RD; Grigoriadis A; Mackay A; Fenwick K; Ashworth A; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    Genes Chromosomes Cancer; 2007 Jun; 46(6):607-15. PubMed ID: 17370329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
    Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.
    Orsetti B; Nugoli M; Cervera N; Lasorsa L; Chuchana P; Rougé C; Ursule L; Nguyen C; Bibeau F; Rodriguez C; Theillet C
    Br J Cancer; 2006 Nov; 95(10):1439-47. PubMed ID: 17060936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genomic hybridization analysis of Wilms tumors.
    Steenman M; Redeker B; de Meulemeester M; Wiesmeijer K; Voûte PA; Westerveld A; Slater R; Mannens M
    Cytogenet Cell Genet; 1997; 77(3-4):296-303. PubMed ID: 9284942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays.
    Rassekh SR; Chan S; Harvard C; Dix D; Qiao Y; Rajcan-Separovic E
    Cancer Genet Cytogenet; 2008 Apr; 182(2):84-94. PubMed ID: 18406869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
    Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
    Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.
    Benetkiewicz M; Díaz de Ståhl T; Gördör A; Pfeifer S; Wittmann S; Gessler M; Dumanski JP
    Int J Cancer; 2006 Aug; 119(3):571-8. PubMed ID: 16496407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genomic hybridization and its application to Wilms' tumorigenesis.
    Getman ME; Houseal TW; Miller GA; Grundy PE; Cowell JK; Landes GM
    Cytogenet Cell Genet; 1998; 82(3-4):284-90. PubMed ID: 9858837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.